Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study-Reference-Cited by-同舟云学术

Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study

Published:2019-03-15 Issue:1 Volume:19 Page:
ISSN:1471-2261
Container-title:BMC Cardiovascular Disorders
language:en
Short-container-title:BMC Cardiovasc Disord

Author:

Hamoui Omar^ORCID,Omar Mohamed I.,Raal Frederick J.,Rashed Wafa,Kane Abdoul,Alami Mohamed,Abreu Paula,Mashhoud Walid,Alsheikh-Ali Alawi A.

Funder

Pfizer Gulf

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12872-019-1034-2.pdf

Reference30 articles.

1. Heart Protection Study Collaboration Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.

2. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–59.

3. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

4. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.

5. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Barriers to accessibility of medicines for hyperlipidemia in low- and middle-income countries;PLOS Global Public Health;2024-02-12

2. Clinical characteristics and statin eligibility of patients under 50 with ST‐elevation myocardial infarction;Clinical Cardiology;2024-02

3. The burden of metabolic risk factors in North Africa and the Middle East, 1990–2019: findings from the Global Burden of Disease Study;eClinicalMedicine;2023-06

4. Prevalence of hypertension in a sample of community members in a low-income peri-urban setting in Gaborone, Botswana;Journal of Public Health in Africa;2023-03-01

5. Risk factors associated with the incidence and prevalence of hypertension in Ghana: an integrated review (2016-2021);International Journal of Environmental Health Research;2022-05-16